CN101088561A - 抗丙型肝炎病毒抗体及其用途 - Google Patents

抗丙型肝炎病毒抗体及其用途 Download PDF

Info

Publication number
CN101088561A
CN101088561A CNA2007101063440A CN200710106344A CN101088561A CN 101088561 A CN101088561 A CN 101088561A CN A2007101063440 A CNA2007101063440 A CN A2007101063440A CN 200710106344 A CN200710106344 A CN 200710106344A CN 101088561 A CN101088561 A CN 101088561A
Authority
CN
China
Prior art keywords
antibody
antibodies
hepatitis
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007101063440A
Other languages
English (en)
Chinese (zh)
Inventor
C·赖特尔
F·哈伯泽策尔
A·富尔尼勒
C·特列波
C·德格朗热
G·安绍斯普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Connex Gesellschaft zur Optimierung von Forschung und Entwicklung mbH
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Connex Gesellschaft zur Optimierung von Forschung und Entwicklung mbH
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connex Gesellschaft zur Optimierung von Forschung und Entwicklung mbH, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Connex Gesellschaft zur Optimierung von Forschung und Entwicklung mbH
Publication of CN101088561A publication Critical patent/CN101088561A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA2007101063440A 1998-07-21 1999-07-20 抗丙型肝炎病毒抗体及其用途 Pending CN101088561A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98113595 1998-07-21
EP98113595.7 1998-07-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB99808641XA Division CN1325517C (zh) 1998-07-21 1999-07-20 抗丙型肝炎病毒抗体及其用途

Publications (1)

Publication Number Publication Date
CN101088561A true CN101088561A (zh) 2007-12-19

Family

ID=8232320

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007101063440A Pending CN101088561A (zh) 1998-07-21 1999-07-20 抗丙型肝炎病毒抗体及其用途
CNB99808641XA Expired - Fee Related CN1325517C (zh) 1998-07-21 1999-07-20 抗丙型肝炎病毒抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB99808641XA Expired - Fee Related CN1325517C (zh) 1998-07-21 1999-07-20 抗丙型肝炎病毒抗体及其用途

Country Status (7)

Country Link
US (3) US6951646B1 (https=)
EP (1) EP1097172A1 (https=)
JP (1) JP4593783B2 (https=)
CN (2) CN101088561A (https=)
AU (1) AU5285899A (https=)
CA (1) CA2339045A1 (https=)
WO (1) WO2000005266A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974246A (zh) * 2014-04-01 2015-10-14 中国科学院上海巴斯德研究所 一种中和丙型肝炎病毒的全人单克隆抗体及其用途
CN107074964A (zh) * 2014-09-05 2017-08-18 医药研究委员会 抗丙型肝炎抗体及其抗原结合片段

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
US7101551B2 (en) 2000-02-14 2006-09-05 Mitsubishi Pharma Corporation Remedies for hepatitis C
IL137522A (en) * 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu Human monoclonal antibody against hepatitis c virus e2 glycoprotein
EP1178116A1 (en) * 2000-08-03 2002-02-06 Hybrigenics S.A. Sid nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof
GB0021859D0 (en) * 2000-09-06 2000-10-18 Imp College Innovations Ltd Methods
GB0114629D0 (en) * 2001-06-15 2001-08-08 Pfizer Ltd Method
ITRM20020049A1 (it) 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
WO2004064608A2 (en) * 2003-01-17 2004-08-05 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
WO2004087760A1 (en) 2003-04-01 2004-10-14 Inserm (Institut National De La Sante De La Reche Rche Medicale) Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
CA2572881A1 (en) * 2004-07-08 2006-01-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Antigen binding proteins directed against scavenger receptor b1 that inhibit hcv replication
AU2006301171B9 (en) * 2005-10-07 2012-03-29 Proyecto De Biomedicina Cima, S.L. Immunostimulatory combination for the prophylactics and treatment of hepatitis C
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
JP5642972B2 (ja) * 2007-02-21 2014-12-17 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
AU2009324092A1 (en) 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
WO2010129033A2 (en) * 2009-04-29 2010-11-11 Calmune Corporation Modified antibodies for passive immunotherapy
EP2495256A4 (en) * 2009-10-30 2013-09-25 Toray Industries ANTIBODIES WITH HEMMETAL EFFECT ON INFECTIONS WITH HEPATITIS C VIRUS (HCV) AND ITS USE
WO2011147863A1 (en) 2010-05-25 2011-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN103308697B (zh) * 2013-06-09 2014-11-26 卫生部北京医院 检测抗丙型肝炎病毒编码的非结构蛋白ns3和ns5的天然双特异性抗体的试剂盒
CN103472233A (zh) * 2013-06-21 2013-12-25 温州大学 丙型肝炎检测试剂盒及其应用
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
CN107286238B (zh) * 2017-08-07 2019-11-26 广州泰诺迪生物科技有限公司 抗hcv广谱中和抗体的制备、检测以及应用
EP3810649A1 (en) 2018-06-22 2021-04-28 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
WO2020020281A1 (zh) 2018-07-25 2020-01-30 信达生物制药(苏州)有限公司 抗tigit抗体及其用途
FI3898668T3 (fi) * 2018-12-19 2023-11-28 Humabs Biomed Sa B-hepatiittivirusta neutraloivia vasta-aineita ja niiden käyttöjä
RS67553B1 (sr) 2018-12-20 2026-01-30 Humabs Biomed Sa Kombinovana hbv terapija
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
BR112022017174A2 (pt) 2020-02-27 2022-10-18 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
CN121851171A (zh) 2020-05-12 2026-04-14 正大天晴药业集团股份有限公司 St2抗原结合蛋白
KR20230119179A (ko) * 2020-12-10 2023-08-16 우시 바이올로직스 아일랜드 리미티드 P-캐드히린에 대한 항체 및 이의 용도
TW202330617A (zh) 2021-11-25 2023-08-01 大陸商正大天晴藥業集團股份有限公司 抗Siglec-15抗體及其應用
WO2023173393A1 (zh) 2022-03-18 2023-09-21 北京天广实生物技术股份有限公司 结合b7-h3的抗体及其用途
CN118684767B (zh) * 2024-06-27 2025-02-18 山东省大健康精准医疗产业技术研究院 一种丙肝核心抗原单链抗体及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE520499C (de) 1929-09-14 1931-03-11 Heinrich Elsner Vorrichtung zum Biegen von Pappe, Fiber u. dgl.
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
ES2174957T5 (es) 1994-07-29 2006-12-16 Innogenetics N.V. Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico.
US6747136B2 (en) * 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
AU1462300A (en) 1998-11-05 2000-05-22 Board Of Trustees Of The Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
AU2001292667A1 (en) 2000-09-13 2002-03-26 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974246A (zh) * 2014-04-01 2015-10-14 中国科学院上海巴斯德研究所 一种中和丙型肝炎病毒的全人单克隆抗体及其用途
CN107074964A (zh) * 2014-09-05 2017-08-18 医药研究委员会 抗丙型肝炎抗体及其抗原结合片段

Also Published As

Publication number Publication date
JP2002521391A (ja) 2002-07-16
CN1309664A (zh) 2001-08-22
US20060153833A1 (en) 2006-07-13
WO2000005266A1 (en) 2000-02-03
AU5285899A (en) 2000-02-14
EP1097172A1 (en) 2001-05-09
CN1325517C (zh) 2007-07-11
US6951646B1 (en) 2005-10-04
CA2339045A1 (en) 2000-02-03
US7507408B2 (en) 2009-03-24
JP4593783B2 (ja) 2010-12-08
US20090104188A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
CN1325517C (zh) 抗丙型肝炎病毒抗体及其用途
Burioni et al. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments
EP1476468B1 (en) Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
JP2022507836A (ja) 新規の抗ジカウイルス抗体及びその使用
US6538114B1 (en) Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
AU2002243259B2 (en) Monoclonal antibodies specific for the E2 glycoprotein of hepatitis C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
US20090130123A1 (en) Antibodies to west nile virus polypeptides
US20140046034A1 (en) Antibody having activity of inhibiting hepatitus c virus (hcv) infection and use thereof
WO1993006488A1 (en) Peptide based hepatitis c virus immunoassays
US7282205B2 (en) Anti-hepatitis A virus antibodies
AU2002243259A1 (en) Monoclonal antibodies specific for the E2 glycoprotein of hepatitis C virus and their use in the diagnosis, treatment, and prevention of hepatitis C
WO2008079890A1 (en) Hepatitis c virus (hcv) inhibitory monoclonal antibody and bindable ligand thereof
US20170107273A1 (en) Antibody having infection-inhibiting activity against hepatitis c virus
CN107286237B (zh) 一种抗丙型肝炎病毒抗体的获取以及应用
WO2002059340A1 (en) Immunopolypeptides to hepatitis c virus
HK1241897A (en) A novel neutralizing human monoclonal antibody 8d6 against hcv infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071219